XtalPi (2228.HK), a leading AI and robotics-driven R&D platform, and VISEN Pharmaceuticals (2561.HK), a biopharmaceutical company dedicated to the endocrine field, today announced a strategic collaboration and project agreement. The partnership, valued at tens of millions of RMB, will advance through key R&D milestones to accelerate the discovery and clinical transformation of innovative therapies for high-value endocrine and metabolic targets.
The collaboration aims to capture the rapidly expanding endocrine market—projected to grow from $95.9 billion in 2024 to nearly $200 billion by 2031—by addressing unmet clinical needs with next-generation therapies optimized via AI and robotics.
Synergy: AI Efficiency Meets Clinical Insight
The partnership merges XtalPi’s state-of-the-art AI + Robotics platform with VISEN’s deep biological insights and commercialization capabilities.
XtalPi’s Technical Engine: XtalPi will utilize its platform—integrating quantum physics, AI, and automated experimentation—to explore vast chemical spaces. By leveraging large-scale robotic clusters to drive rapid Design-Make-Test-Analyze (DMTA) cycles, the platform will solve complex multi-objective optimization challenges regarding potency, selectivity, and metabolism, significantly shortening the timeline to identify Preclinical Candidates (PCC).
VISEN’s Domain Leadership: As the first and only listed company on the HKEX focused on growth and endocrine disorders, VISEN brings a sophisticated understanding of disease mechanisms and a proven track record. Its core product, Lonapegsomatropin, is the world’s first long-acting growth hormone approved by the FDA for pediatric GHD and is now approved in China with superior efficacy data compared to daily formulations.
Expanding the Horizons of Metabolic Health
The partnership focuses on “AI-defined drugs and clinically-defined value.” By integrating XtalPi’s underlying technology with VISEN’s differentiation strategies, the two companies aim to develop “Made-in-China” medicines with global competitiveness.
“XtalPi is committed to solving drug discovery challenges that are insurmountable by traditional means,” said Dr. Jian Ma, CEO of XtalPi. “VISEN has shown extraordinary professional depth and commercial vision in the endocrine space. We look forward to synergizing our AI + Robotics platform with their clinical insights to bring safer, more effective treatments to patients.”
Mr. Pony Lu, Executive Director and CEO of VISEN Pharmaceuticals, added: “Our collaboration with XtalPi is a proactive step in integrating frontier technologies to enhance our source innovation capabilities. XtalPi’s technical prowess in AI drug discovery is impressive, and we expect this synergy to allow us to explore new therapeutic possibilities more accurately and efficiently.”
About VISEN Pharmaceuticals
VISEN Pharmaceuticals (2561.HK) is an innovative biopharmaceutical company focused on endocrine-related therapies. Committed to “First-in-Class” or “Best-in-Class” solutions, VISEN covers adult and pediatric endocrinology as well as rare endocrine diseases. Headquartered in Suzhou, with offices in Shanghai, Beijing, Hong Kong, and Taipei, the company manages the full value chain from R&D and production to commercialization. VISEN was officially listed on the Main Board of the Hong Kong Stock Exchange on March 21, 2025.
